v3.26.1
Commitments and Contingencies - Quimilza - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Commitments and Contingencies [Line Items]            
Research and development   $ 36,953 $ 21,990 $ 65,388 $ 57,702  
Quimilza            
Commitments and Contingencies [Line Items]            
Development and milestone obligations paid to third party $ 10,000          
Additional development and milestone payments to third party $ 5,000          
Research and development           $ 14,400
Royalty payable on net sales (in percent) 10.00%          
Quimilza | Future Regulatory Approval and Sales Milestones            
Commitments and Contingencies [Line Items]            
Possible future milestone payment       35,000    
Quimilza | Future Regulatory Approval, Filing Application For Marketing Authorization Milestone | U.S.            
Commitments and Contingencies [Line Items]            
Possible future milestone payment       5,000    
Quimilza | Future Regulatory Approval, Filing Application For Marketing Authorization Milestone | E.U.            
Commitments and Contingencies [Line Items]            
Possible future milestone payment       5,000    
Quimilza | Future Regulatory Approval, Sales Milestones            
Commitments and Contingencies [Line Items]            
Possible future milestone payment       $ 25,000